Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis

Premature Coronary Artery Disease (CAD) in Severe Psoriasis

NCT00893126 ·Status: COMPLETED

Cytokines and Vascular Inflammation in Psoriasis

NCT02305953 ·Status: COMPLETED

Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents

NCT01356758 ·Status: COMPLETED

Analysis Of The Influence Of Metabolic Syndrome On Treatment Efficacy With Anti-Tnf In Moderate-Severe Psoriasis In Real Clinical Practice.

NCT01753245 ·Status: UNKNOWN

Cytokine Expression in Psoriasis Patients with and Without Joint Involvement

NCT05307809 ·Status: RECRUITING ·Phase: NA

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis

NCT03337022 ·Status: COMPLETED ·Phase: PHASE1

Monitoring and Modifying Atherosclerosis in Psoriasis Patients Study

NCT01522742 ·Status: TERMINATED

Personal Precise Treatment on Psoriasis and Psoriatic Arthritis

NCT04915105 ·Status: UNKNOWN ·Phase: NA

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

NCT01700985 ·Status: COMPLETED ·Phase: PHASE2

Association Between the Occurrence of a Clinical RElapse and Gut MIcrobiota Modifications: a Cohort Study of Patients With pSOriasis

NCT06055699 ·Status: NOT_YET_RECRUITING

An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis

NCT01555606 ·Status: COMPLETED

A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)

NCT01225731 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.

NCT01899755 ·Status: COMPLETED ·Phase: PHASE1

Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis

NCT00998829 ·Status: COMPLETED

A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT02223039 ·Status: COMPLETED ·Phase: PHASE2

Serum Level of Bioactive Mediators and Urinary Biopyrins in Psoriasis

NCT03889938 ·Status: UNKNOWN

Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis

NCT05125679 ·Status: TERMINATED ·Phase: PHASE4

Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

NCT02502188 ·Status: TERMINATED ·Phase: PHASE1

Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast

NCT03442088 ·Status: COMPLETED ·Phase: PHASE2

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis

NCT00848055 ·Status: COMPLETED ·Phase: PHASE1

COVID-19 Associated With Psoriasis

NCT05961605 ·Status: UNKNOWN

Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors

NCT07041112 ·Status: COMPLETED

Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis

NCT01139918 ·Status: COMPLETED

The Study of Koebner in Patients With Psoriasis and Psoriatic Arthritis

NCT05589298 ·Status: COMPLETED

Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis

NCT01617018 ·Status: COMPLETED